Статья

Targeting VCAM-1 with chimeric antigen receptor and regulatory T cell for abdominal aortic aneurysm treatment

Qingwei GangDepartment of Vascular Surgery, the First Hospital of China Medical University, Shenyang, ChinaYu LunDepartment of Vascular Surgery, the First Hospital of China Medical University, Shenyang, ChinaXiaoxu ZhangSchool of Chemical Engineering, Ocean Technology and Life Science, Dalian University of Technology, Panjin, ChinaJamol UzokovRepublican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, Tashkent, UzbekistanHan JiangDepartment of Vascular Surgery, the First Hospital of China Medical University, Shenyang, ChinaYuchen HeDepartment of Vascular Surgery, the First Hospital of China Medical University, Shenyang, ChinaShikai ShenDepartment of Vascular Surgery, the First Hospital of China Medical University, Shenyang, ChinaShiyue WangDepartment of Vascular Surgery, the First Hospital of China Medical University, Shenyang, ChinaPhilipp ErhartDepartment of Vascular and Endovascular Surgery, University of Heidelberg, Heidelberg, GermanyDittmar BöcklerDepartment of Vascular and Endovascular Surgery, University of Heidelberg, Heidelberg, GermanyYuemeng LiDepartment of Vascular Surgery, Central Hospital of Dalian University of Technology, Dalian, ChinaYanshuo HanDepartment of Vascular Surgery, Central Hospital of Dalian University of Technology, Dalian, China. [email protected]Jian ZhangDepartment of Vascular Surgery, the First Hospital of China Medical University, Shenyang, China. [email protected]

Communications Biologyjournal2025en

ABI

Аннотация

Abdominal aortic aneurysm (AAA) is a life-threatening condition characterized by the dilation of the abdominal aorta, leading to a high risk of rupture. Current treatment options are limited, particularly for patients ineligible for surgical interventions. This study explores a novel immunotherapeutic approach using chimeric antigen receptor Treg cells targeting vascular cell adhesion molecule-1 (VCAM-1) to mitigate AAA progression. By leveraging the specificity and regulatory function of CAR-Treg cells, our research aims to modulate the immune response and reduce inflammation in the aneurysmal wall. Results from preclinical mouse models demonstrated that CAR-Treg cells effectively homed to the aneurysmal site, suppressed local inflammation, and decreased aortic dilation compared to control groups. These findings suggest that CAR-Treg cell therapy could provide a promising, non-surgical treatment option for AAA patients, addressing a critical unmet need in cardiovascular disease management. This study investigates CAR-Treg cells targeting VCAM-1 as a novel treatment for abdominal aortic aneurysm (AAA). Preclinical results show CAR-Treg cells effectively reduce inflammation and aortic dilation, offering a non-surgical treatment option for AAA.

Перевод пока недоступен

Темы

CAR-T cell therapy research

Идентификаторы

DOI: 10.1038/s42003-025-08604-9

Цитирования и источники

Цитирований: 1 Использованных источников: 46

Показатели — AkademScholar · Скоро